BioStock: Abliva receives FDA Fast Track designation

Swedish biotech Abliva recently received FDA Fast Track designation for KL1333 – the company’s lead drug candidate for mitochondrial disease. KL1333 is currently being evaluated in the potentially registrational phase II study FALCON. BioStock reached out to CEO Ellen K. Donnelly for a comment.

Read the full interview with Ellen K. Donnelly at biostock.se:

https://www.biostock.se/en/2023/09/abliva-receives-fda-fast-track-designation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/